NCT06326008View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 15, 2024

Primary Completion Date

June 15, 2026

Study Completion Date

December 30, 2026

Conditions

B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in Relapse

Interventions

DRUG

Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy

Peripheral blood mononuclear cells for the production of CD19 CAR T cells and CD22 CAR T cells are collected from donors and haematopoietic stem cells are collected from donors.

All Listed Sponsors

lead

Beijing GoBroad Hospital

OTHER